Stockreport

AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites

AzurRx BioPharma, Inc.  (AZRX) 
Last azurrx biopharma, inc. earnings: 11/14 04:31 pm Check Earnings Report
PDF On track to initiate the OPTION 2 trial by the end of Q2 2020OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsul [Read more]